AIM: Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. MATERIALS & METHODS: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. RESULTS: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. CONCLUSION: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.
AIM: Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. MATERIALS & METHODS: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. RESULTS: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. CONCLUSION: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.
Authors: Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso Journal: Semin Immunol Date: 2017-10-09 Impact factor: 11.130
Authors: Fiona Y Glassman; Jennifer L Schneider; Radha Ramakrishnan; Robert K Dingman; Murali Ramanathan; Richard B Bankert; Sathy V Balu-Iyer Journal: J Pharm Sci Date: 2018-04-09 Impact factor: 3.534
Authors: Silvia Rodriguez-Fernandez; Irma Pujol-Autonell; Ferran Brianso; David Perna-Barrull; Mary Cano-Sarabia; Sonia Garcia-Jimeno; Adrian Villalba; Alex Sanchez; Eva Aguilera; Federico Vazquez; Joan Verdaguer; Daniel Maspoch; Marta Vives-Pi Journal: Front Immunol Date: 2018-02-14 Impact factor: 7.561
Authors: Anja Ten Brinke; Marc Martinez-Llordella; Nathalie Cools; Catharien M U Hilkens; S Marieke van Ham; Birgit Sawitzki; Edward K Geissler; Giovanna Lombardi; Piotr Trzonkowski; Eva Martinez-Caceres Journal: Front Immunol Date: 2019-02-22 Impact factor: 7.561
Authors: Silvia Rodriguez-Fernandez; Marta Murillo; Adrian Villalba; David Perna-Barrull; Mary Cano-Sarabia; Laia Gomez-Muñoz; Eva Aguilera; Daniel Maspoch; Federico Vazquez; Joan Bel; Marta Vives-Pi Journal: Front Immunol Date: 2019-11-28 Impact factor: 7.561
Authors: Noemi Poerio; Federica De Santis; Alice Rossi; Serena Ranucci; Ida De Fino; Ana Henriquez; Marco M D'Andrea; Fabiana Ciciriello; Vincenzina Lucidi; Roberto Nisini; Alessandra Bragonzi; Maurizio Fraziano Journal: Front Immunol Date: 2020-10-02 Impact factor: 7.561